Payment overview · 2025
General Payments
$378.97
21 reported records · 11 companies
Healthcare provider profile · identity verified
Calin G Badea, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HINESVILLE, GA · NPI 1346239639
Verified facts
What the public records show
CMS Open Payments records show Calin G Badea, M.D. received $378.97 in general payments during 2025 across 21 reported records.
Novo Nordisk Inc accounted for 27.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 216 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 389 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 389 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 208 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $103.80 | 27.4% | 6 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $52.80 | 13.9% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $48.18 | 12.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.07 | 9.8% | 2 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $32.66 | 8.6% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $21.80 | 5.8% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $20.51 | 5.4% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.87 | 4.7% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $16.19 | 4.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.27 | 3.8% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.82 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $378.97 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $57.87 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $57.87 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $52.80 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $48.18 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.93 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $37.07 | 2 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $32.66 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| INJECTAFER Normalized: injectafer |
Drug | Daiichi Sankyo Inc. | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $17.87 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $16.19 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.20 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $13.82 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 216 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 389 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 63 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 208 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
216 | 52 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
389 | 91 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
389 | 91 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
122 | 23 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
208 | 47 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1002 | 236 |
| Amlodipine Besylate | Amlodipine Besylate | 860 | 216 |
| Pantoprazole Sodium | Pantoprazole Sodium | 543 | 142 |
| Furosemide | Furosemide | 517 | 128 |
| Potassium Chloride | Potassium Chloride | 516 | 117 |
| Metformin Hcl | Metformin Hcl | 454 | 114 |
| Losartan Potassium | Losartan Potassium | 444 | 116 |
| Gabapentin | Gabapentin | 424 | 105 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 412 | 88 |
| Jardiance | Empagliflozin | 389 | 91 |
| Levothyroxine Sodium | Levothyroxine Sodium | 375 | 79 |
| Lisinopril | Lisinopril | 369 | 84 |
| Famotidine | Famotidine | 360 | 65 |
| Carvedilol | Carvedilol | 345 | 77 |
| Eliquis | Apixaban | 340 | 72 |
| Clopidogrel | Clopidogrel Bisulfate | 329 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 310 | 69 |
| Tramadol Hcl | Tramadol Hcl | 307 | 86 |
| Omeprazole | Omeprazole | 291 | 79 |
| Prednisone | Prednisone | 290 | 147 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 265 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 253 | 65 |
| Trazodone Hcl | Trazodone Hcl | 220 | 57 |
| Farxiga | Dapagliflozin Propanediol | 216 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 214 | 53 |
| Mirtazapine | Mirtazapine | 212 | 55 |
| Ozempic | Semaglutide | 208 | 47 |
| Donepezil Hcl | Donepezil Hcl | 197 | 30 |
| Sertraline Hcl | Sertraline Hcl | 196 | 41 |
| Spironolactone | Spironolactone | 186 | 45 |
| Alprazolam | Alprazolam | 178 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 170 | 40 |
| Glipizide | Glipizide | 169 | 39 |
| Olanzapine | Olanzapine | 167 | 26 |
| Simvastatin | Simvastatin | 167 | 32 |
| Metoprolol Succinate | Metoprolol Succinate | 159 | 46 |
| Hydralazine Hcl | Hydralazine Hcl | 158 | 37 |
| Montelukast Sodium | Montelukast Sodium | 135 | 33 |
| Allopurinol | Allopurinol | 133 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 133 | 46 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 128 | 38 |
| Alendronate Sodium | Alendronate Sodium | 123 | 28 |
| Ezetimibe | Ezetimibe | 122 | 30 |
| Trulicity | Dulaglutide | 122 | 23 |
| Linzess | Linaclotide | 121 | 25 |
| Latanoprost | Latanoprost | 119 | 20 |
| Levetiracetam | Levetiracetam | 115 | 21 |
| Tizanidine Hcl | Tizanidine Hcl | 113 | 33 |
| Buspirone Hcl | Buspirone Hcl | 112 | 35 |
| Quetiapine Fumarate | Quetiapine Fumarate | 105 | 28 |
| Clonidine Hcl | Clonidine Hcl | 103 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 95 | 22 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 92 | 38 |
| Ondansetron Hcl | Ondansetron Hcl | 91 | 47 |
| Fluconazole | Fluconazole | 90 | 49 |
| Escitalopram Oxalate | Escitalopram Oxalate | 88 | 19 |
| Ropinirole Hcl | Ropinirole Hcl | 86 | 19 |
| Memantine Hcl | Memantine Hcl | 73 | 12 |
| Entresto | Sacubitril/Valsartan | 71 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 71 | 24 |
| Pregabalin | Pregabalin | 69 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 14 |
| Meloxicam | Meloxicam | 68 | 33 |
| Atenolol | Atenolol | 65 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 65 | 23 |
| Pravastatin Sodium | Pravastatin Sodium | 65 | 19 |
| Mounjaro | Tirzepatide | 63 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 61 | 15 |
| Lovastatin | Lovastatin | 61 | 13 |
| Baclofen | Baclofen | 59 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 59 | 18 |
| Risperidone | Risperidone | 59 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 59 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 58 | 18 |
| Azithromycin | Azithromycin | 54 | 42 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 54 | 45 |
| Ondansetron Odt | Ondansetron | 54 | 19 |
| Lorazepam | Lorazepam | 53 | 16 |
| Warfarin Sodium | Warfarin Sodium | 50 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 42 |
| Novolog Flexpen | Insulin Aspart | 49 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 46 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 23 |
| Divalproex Sodium | Divalproex Sodium | 44 | suppressed |
| Glipizide Er | Glipizide | 44 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 43 | 12 |
| Diazepam | Diazepam | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 41 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 41 | 16 |
| Oxybutynin Chloride | Oxybutynin Chloride | 41 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Finasteride | Finasteride | 39 | suppressed |
| Novolin R | Insulin Regular, Human | 39 | suppressed |
| Xarelto | Rivaroxaban | 36 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 26 |
| Brimonidine Tartrate | Brimonidine Tartrate | 35 | suppressed |
| Colchicine | Colchicine | 35 | suppressed |
| Nystatin | Nystatin | 34 | 20 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 34 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 33 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 33 | 17 |
| Glimepiride | Glimepiride | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 32 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 32 | 12 |
| Risperdal Consta | Risperidone Microspheres | 32 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 31 | 12 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 31 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 31 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Gemfibrozil | Gemfibrozil | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 15 |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 13 |
| Lamotrigine | Lamotrigine | 29 | suppressed |
| Levofloxacin | Levofloxacin | 29 | 22 |
| Enalapril Maleate | Enalapril Maleate | 28 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 27 | suppressed |
| Levemir Flexpen | Insulin Detemir | 27 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 27 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 26 | 13 |
| Digoxin | Digoxin | 26 | suppressed |
| Naproxen Sodium | Naproxen Sodium | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Rivastigmine | Rivastigmine | 26 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | suppressed |
| Naproxen | Naproxen | 25 | 11 |
| Sucralfate | Sucralfate | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Bupropion Xl | Bupropion Hcl | 24 | suppressed |
| Metolazone | Metolazone | 24 | suppressed |
| Novolog | Insulin Aspart | 24 | 13 |
| Calcitriol | Calcitriol | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 22 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 22 | suppressed |
| Timolol Maleate | Timolol Maleate | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 20 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 20 | suppressed |
| Haloperidol | Haloperidol | 20 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 19 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | 15 |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 15 |
| Telmisartan | Telmisartan | 19 | suppressed |
| Fenofibrate | Fenofibrate | 18 | suppressed |
| Lacosamide | Lacosamide | 18 | suppressed |
| Nystop | Nystatin | 18 | 13 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 17 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Dutasteride | Dutasteride | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 17 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 16 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 15 | 13 |
| Exemestane | Exemestane | 15 | suppressed |
| Gemtesa | Vibegron | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 15 | suppressed |
| Synthroid | Levothyroxine Sodium | 15 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Vascepa | Icosapent Ethyl | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 14 | suppressed |
| Celecoxib | Celecoxib | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 14 | suppressed |
| Neupro | Rotigotine | 14 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Captopril | Captopril | 13 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Irbesartan | Irbesartan | 13 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 13 | suppressed |
| Movantik | Naloxegol Oxalate | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Rybelsus | Semaglutide | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | 11 |
| Vraylar | Cariprazine Hcl | 13 | suppressed |
| Admelog Solostar | Insulin Lispro | 12 | suppressed |
| Calcium Acetate | Calcium Acetate | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Ibuprofen | Ibuprofen | 11 | suppressed |
| Levemir | Insulin Detemir | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Minoxidil | Minoxidil | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
| Repatha Sureclick | Evolocumab | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Ubrelvy | Ubrogepant | 11 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $378.97 · 21 records | Novo Nordisk Inc | CAPLYTA, FANAPT, FARXIGA, INJECTAFER, INSPIRE, JARDIANCE, KRYSTEXXA, MOUNJARO, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, Wegovy, XIFAXAN, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error